A Randomized, Participant- and Investigator-blinded, Sponsor Open-label, Placebo-controlled, Single and Multiple Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
Latest Information Update: 20 May 2024
At a glance
- Drugs XXB 750 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 07 Feb 2024 Status changed from active, no longer recruiting to completed.
- 17 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Aug 2023 Planned End Date changed from 24 Jan 2024 to 21 Jan 2024.